INmune Bio Inc.
US ˙ NasdaqCM ˙ US45782T1051

SecurityINMB / INmune Bio Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership44,611 shares
Latest Disclosed Value $ 50,411
Morgan Stanley reports 63.59% decrease in ownership of INMB / INmune Bio Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 44,611 shares of INmune Bio Inc. (US:INMB) valued at $50,410 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 122,512 shares of INmune Bio Inc.. This represents a change in shares of -63.59% during the quarter. The current value of the position is $60,225 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F INMUNE BIO COM 45782T105 44,611 -77,901 -63.59 50 -73.82 0.0000
2026-05-27 2025-12-31 13F/A-1 INMUNE BIO COM 45782T105 122,512 46,802 61.82 191 22.44 0.0000
2026-02-13 2025-12-31 13F INMUNE BIO COM 45782T105 122,512 46,802 191 0.0000
2026-05-27 2025-09-30 13F/A-1 INMUNE BIO COM 45782T105 75,710 -27,028 -26.31 157 -34.18 0.0000
2025-11-14 2025-09-30 13F INMUNE BIO COM 45782T105 75,710 -27,028 157 0.0000
2025-08-15 2025-06-30 13F INMUNE BIO COM 45782T105 102,738 18,274 21.64 237 -64.04 0.0000
2025-05-15 2025-03-31 13F INMUNE BIO COM 45782T105 84,464 -70,662 -45.55 660 -8.98 0.0000
2025-05-15 2024-12-31 13F/A-1 INMUNE BIO COM 45782T105 155,126 62,982 68.35 724 45.97 0.0001
2025-02-14 2024-12-31 13F INMUNE BIO COM 45782T105 155,126 62,982 724 0.0001
2025-05-14 2024-09-30 13F/A-2 INMUNE BIO COM 45782T105 92,144 63,769 224.74 497 98.40 0.0000
2025-02-14 2024-09-30 13F/A-1 INMUNE BIO COM 45782T105 92,144 63,769 497 0.0000
2024-11-14 2024-09-30 13F INMUNE BIO COM 45782T105 92,144 63,769 497 0.0000
2025-05-14 2024-06-30 13F/A-2 INMUNE BIO COM 45782T105 28,375 896 3.26 250 -22.36 0.0000
2024-10-17 2024-06-30 13F/A-1 INMUNE BIO COM 45782T105 28,375 896 250 0.0000
2024-08-14 2024-06-30 13F INMUNE BIO COM 45782T105 28,375 896 250 0.0000
2024-10-17 2024-03-31 13F/A-2 INMUNE BIO COM 45782T105 27,479 14,676 114.63 323 123.61 0.0000
2024-08-16 2024-03-31 13F/A-1 INMUNE BIO COM 45782T105 27,479 14,676 323 0.0000
2024-05-15 2024-03-31 13F INMUNE BIO COM 45782T105 27,479 14,676 323 0.0000
2024-08-16 2023-12-31 13F/A-1 INMUNE BIO COM 45782T105 12,803 8,722 213.72 144 433.33 0.0000
2024-02-13 2023-12-31 13F INMUNE BIO COM 45782T105 12,803 8,722 144 0.0000
2023-11-15 2023-09-30 13F INMUNE BIO COM 45782T105 4,081 -913 -18.28 28 -40.00 0.0000
2023-08-14 2023-06-30 13F INMUNE BIO COM 45782T105 4,994 177 3.67 45 45.16 0.0000
2023-05-15 2023-03-31 13F INMUNE BIO COM 45782T105 4,817 1,829 61.21 31 72.22 0.0000
2023-02-14 2022-12-31 13F INMUNE BIO COM 45782T105 2,988 -126,012 -97.68 19 -97.75 0.0000
2022-11-14 2022-09-30 13F INMUNE BIO COM 45782T105 129,000 -79,282 -38.06 800 -56.55 0.0001
2022-10-27 2022-06-30 13F/A-1 INMUNE BIO COM 45782T105 208,282 -92,199 -30.68 1,841 -27.23 0.0002
2022-08-15 2022-06-30 13F INMUNE BIO COM 45782T105 208,282 -92,199 1,841 0.0000
2022-10-27 2022-03-31 13F/A-1 INMUNE BIO COM 45782T105 300,481 -78,006 -20.61 2,530 -34.47 0.0003
2022-05-13 2022-03-31 13F INMUNE BIO COM 45782T105 300,481 -78,006 2,530 0.0003
2022-02-14 2021-12-31 13F INMUNE BIO COM 45782T105 378,487 353,856 1,436.63 3,861 707.74 0.0005
2021-11-15 2021-09-30 13F INMUNE BIO COM 45782T105 24,631 13,088 113.38 478 135.47 0.0001
2021-08-23 2021-06-30 13F/A-1 INMUNE BIO COM 45782T105 11,543 8,450 273.20 203 448.65 0.0000
2021-08-16 2021-06-30 13F INMUNE BIO COM 45782T105 11,543 8,450 203 0.0000
2021-05-17 2021-03-31 13F INMUNE BIO COM 45782T105 3,093 1,526 97.38 37 37.04 0.0000
2021-02-16 2020-12-31 13F INMUNE BIO COM 45782T105 1,567 567 56.70 27 170.00 0.0000
2020-11-13 2020-09-30 13F INMUNE BIO COM 45782T105 1,000 1,000 10 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.